[Modern anti-glaucoma drugs and their secondary effects].
Mermoud
A
A
Hôpital ophtalmique Jules Gonin, Service universitaire d'ophtalmologie, Lausanne, Suisse.
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology / Q000627:therapeutic use*; D000068438:Brimonidine Tartrate; D002257:Carbonic Anhydrase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D015237:Dinoprost / Q000031:analogs & derivatives*; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D011810:Quinoxalines / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use
D000316:Adrenergic alpha-Agonists; D002257:Carbonic Anhydrase Inhibitors; D011810:Quinoxalines; D013449:Sulfonamides; D013876:Thiophenes; D000068438:Brimonidine Tartrate; C062765:dorzolamide; D015237:Dinoprost
Les médicaments antiglaucomateux modernes et leurs effets secondaires.